Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Chuan Gu, Gongyan Chen et al.|The Lancet Respiratory Medicine|2022Cited by 235
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lei Nie, Lin Wu et al.|Journal of Clinical Oncology|2022Cited by 177
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Chuan Gu, Gongyan Chen et al.|Journal of Thoracic Oncology|2022Cited by 79
Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An UpdateNa Li, Hui Zhao|Frontiers in Medicine|2021Cited by 78
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Jason Yang, Ziping Wang et al.|Nature Cancer|2023Cited by 34